104 related articles for article (PubMed ID: 6850654)
21. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
22. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia.
Karbasian-Esfahani M; Wiernik PH; Novik Y; Paietta E; Dutcher JP
Cancer; 2004 Sep; 101(6):1414-9. PubMed ID: 15368329
[TBL] [Abstract][Full Text] [Related]
23. [Preliminary evaluation of adverse effects after administration of arabinoside cytosine (Ara-C) in high doses to children with acute myelogenous leukemia].
Wysocki M; Kurylak A; Pilecki O; Balcar-Boroń A
Acta Haematol Pol; 1994; 25(1):37-42. PubMed ID: 8209612
[TBL] [Abstract][Full Text] [Related]
24. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
[TBL] [Abstract][Full Text] [Related]
25. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
[TBL] [Abstract][Full Text] [Related]
26. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study.
Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727
[TBL] [Abstract][Full Text] [Related]
27. Neutrophil recovery time and adverse side effects in acute leukemia patients treated with intensive chemotherapy and concomitant G or GM-CSF.
Alvarado Ibarra ML; Borbolla Escoboza JR; López-Hernández MA; González-Avante CM; FloresChapa JD; Trueba Christy E; Anaya Cuellar I
Rev Invest Clin; 1999; 51(2):77-80. PubMed ID: 10410585
[TBL] [Abstract][Full Text] [Related]
28. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.
Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE
Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751
[TBL] [Abstract][Full Text] [Related]
29. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
[TBL] [Abstract][Full Text] [Related]
30. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
[TBL] [Abstract][Full Text] [Related]
33. Severe central nervous system toxicity from high-dose cytarabine: expressive aphasia occurring after the second day of treatment.
Watson PR; Brubaker LH; Yaghmai F
Cancer Treat Rep; 1985 Mar; 69(3):313-4. PubMed ID: 3978659
[TBL] [Abstract][Full Text] [Related]
34. Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.
Capizzi RL; Yang JL; Cheng E; Bjornsson T; Sahasrabudhe D; Tan RS; Cheng YC
J Clin Oncol; 1983 Dec; 1(12):763-71. PubMed ID: 6668493
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Yoshida T; Nakamura S; Ohtake S; Ito K; Kobayashi K; Kanno M; Hirai J; Tachimori K; Matsuda T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
[TBL] [Abstract][Full Text] [Related]
36. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia.
Rudnick SA; Cadman EC; Capizzi RL; Skeel RT; Bertino JR; McIntosh S
Cancer; 1979 Oct; 44(4):1189-93. PubMed ID: 498009
[TBL] [Abstract][Full Text] [Related]
37. [Acute leukemia complicated by hyperbilirubinemia due to high dose cytosine arabinoside therapy].
Hashimoto M; Seekikawa I; Saito K; Horie S; Ishiyama T; Sugimoto M; Wakabayashi Y; Hirose S
Rinsho Ketsueki; 1989 Feb; 30(2):262-5. PubMed ID: 2746881
[TBL] [Abstract][Full Text] [Related]
38. [High doses of ARA C in the treatment of acute leukemia].
Lobato-Mendizábal E; Ruiz-Argüelles GJ; Marín-López A
Sangre (Barc); 1989 Feb; 34(1):78-9. PubMed ID: 2711290
[No Abstract] [Full Text] [Related]
39. Brachial plexus neuropathy following high-dose cytarabine in acute monoblastic leukemia.
Scherokman B; Filling-Katz MR; Tell D
Cancer Treat Rep; 1985 Sep; 69(9):1005-6. PubMed ID: 2992782
[TBL] [Abstract][Full Text] [Related]
40. Progressive cutaneous herpes simplex infection in acute myeloblastic leukemia. Successful treatment with interferon and cytarabine.
Shalev Y; Berrebi A; Green L; Levin S; Frumkin A; Hurwitz N; Bentwich Z
Arch Dermatol; 1984 Jul; 120(7):922-6. PubMed ID: 6587832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
